Catheter-Associated Infections in Patients on Hemodialysis

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(2):107-117

​ Berezhanskiy B.V.
catheter-associated bloodstream infections hemodialysis dialysis catheters
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(2):107-117

Abstract

Long-term dialysis therapy in patients with chronic kidney disease is usually associated with vascular access problems, mechanic and infectious complications from the use intravascular devices, and increase in antimicrobial resistance. This paper presents a review of incidence rates, risk factors, classification, and preventive measures for dialysis catheter-associated infections.

  • 1. Tokars J.I., Finelli L., Alter M.J., Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2001. Report accessed from http://www.cdc. gov/ncidod/hip/SURVEILL/SURVEILL.HTM
  • 2. Johnson D., MacGinley R., Kay T., et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17:1802-7.
  • 3. Ayus J.C., Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9:1314-7.
  • 4. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
  • 5. Al-Said J, Pagaduan AC. Infection-free hemodialysis: Can it be achieved?. Saudi J Kidney Dis Transpl 2009; 20:677-80.
  • 6. Lok C., Mokrzycki M. Prevention and management of catheter-related infection in hemodialysis patients. Kidney Int 2011; 79:587-98.
  • 7. Centers for Disease Control and Prevention. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings, http://www.cdc.gov/drugresistance/healthcare/default.htm. Accessed on December 9, 2003.
  • 8. Bonomo R.A., Rice D., Whalen C., Linn D., Eckstein E., Shlaes D.M. Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol 1997; 18:757-61.
  • 9. Betjes M. Prevention of catheter-related bloodstream infection in patients on hemodialysis. Nat Rev Nephrol 2011; 7:257–65.
  • 10. Dittmer I.D., Sharp D., McNulty C.M., Williams A.J., Banks B.A. A prospective study of central venous hemodialysis catheter colonisation and peripheral bacteremia. Clin Nephrol 1999; 51:34-9.
  • 11. Hoen B., Paul-Dauphin A., Hestin D., Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-76.
  • 12. Tokars J.I., Miller E.R., Stein G. New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 2002; 30:288-95.
  • 13. Powe N.R., Jaar B., Furth S.L., Hermann J., Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999; 55:1081-90.
  • 14. Белобородов В.Б. Роль современных рекомендаций по профилактике инфекций, связанных с катетеризацией сосудов. Инфекции и антимикробная терапия 2002; 6:177-80.
  • 15. Deshpande K., Hatem C., Ulrich H., et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit Care Med 2005; 33:13-20.
  • 16. Ash S.R. The evolution and function of central venous catheters for dialysis. Seminars in Dialysis 2001; 14:416- 24.
  • 17. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002; 51(No.RR-10):1-29.
  • 18. Mickley V. Central venous catheters: many questions, few answers. Nephrol Dial Transplant 2002; 17:1368-73.
  • 19. Joseph S., Adler S. Vascular access problems in dialysis patients. Pathogenesis and strategies for management. Heart Disease 2001; 3:242-7.
  • 20. Сидоренко С.В. Инфекции, связанные с центральным венозным катетером. Инфекции и антимикробная терапия 2001; 2:24-35.
  • 21. Tanriover B., Carlton D., Saddekni S., et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int 2000; 57:2151-5.
  • 22. Tokars J.I., Klevens R.M. Infections associated with hemodialysis vascular accesses and with catheters used for hemodialysis. In: Seifert H., Jansen B., Farr B.M., editors. Catheter-related infections. 2nd ed. New York: Marcel Dekker; 2004. p. 293-315.
  • 23. Nabi Z., Anwar S., Barhamein M., et al. Catheter related infection in hemodialysis patients. Saudi J Kidney Dis Transpl 2009; 20:1091-5.
  • 24. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108-15.
  • 25. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR 2002; 51:565-7.
  • 26. Brun-Buisson C. New technologies and infection control practices to prevent intravascular catheter-related infections. Am J Resp Crit Care Med 2001; 164:1557-8.
  • 27. Walsh T., Rex J. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 34:600-2.
  • 28. McIntyre C., Hulme L., Taal M., Fluck R. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004; 66:801-5.
  • 29. Руководство по инфекционному контролю в стационаре. Под редакцией Венцель Р., Бревер Т., Бутцлер Ж-П. Пер. с англ. Смоленск: МАКМАХ; 2003. С. 18-20.
  • 30. Blot F. Diagnosis of catheter-related infections. In: Seifert H., Jansen B., Farr B.M., editors. Catheter-related infections. 2nd ed. New York: Marcel Dekker; 2004. Р. 37-72.
  • 31. Safdar N., Maki D. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intens Care Med 2004; 30:62-7.
  • 32. Crnich C., Maki D. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002; 34:1232-42.
  • 33. Beekman S., Henderson D. Infections caused by percutaneous intravascular devices. In: Mandell C., Bennett J., Dolin R. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005. p. 3347-61.
  • 34. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32(9):1249-72.
  • 35. Raad I. Intravascular-catheter-relatcd infections. Lancet 1998; 351:893-8.
  • 36. Donlan R. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33:1387-92.
  • 37. Lyte M., Freestone P., Neal C., et al. Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. Lancet 2003; 361:130-5.
  • 38. Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002; 8:275-81.
  • 39. Масчан А.А. Практический взгляд на проблему катетерных инфекций. Доступна на: URL: http://www.rusanesth.com/genan.
  • 40. Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
  • 41. Бережанский Б., Жевнерев А. Катетер-ассоциированные инфекции кровотока. Клин микробиол и антимикроб химиотер 2006; 8:130-44.
  • 42. Berns J.S., Tokars J.I. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002; 40:886-98.
  • 43. Warren D., Zack J., Mayfield J., et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004; 126:1612-8.
  • 44. Sherertz R., Ely W., Westbrook D., et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132:641-8.
  • 45. Yoo S., Ha M., Choi D., Pai H. Effectiveness of surveillance of central catheter-related bloodstream infection in an ICU in Korea. Infect Control Hosp Epidemiol 2001; 22:433-6.
  • 46. McGee D., Gould M. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123-33.
  • 47. De Gaudio A., Di Filippo A. Device-related infections in critically ill patients. Part 1: prevention of catheter-related bloodstream infections. J Chemother 2003; 5:419-27.
  • 48. O’Grady N., Alexander M., Burns L., et al. Gudelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:1-32.
  • 49. Elliott T. Role of antimicrobial central venous catheters for the prevention of associated infections. J Antimicrob Chemother 1999; 43:441-6.
  • 50. Seifert H., Jansen B., Widmer A.F., Farr B.M. Centralvenous catheters. In: Seifert H., Jansen B., Farr B.M., editors. Catheter-related infections. 2nd ed. New York: Marcel Dekker; 2004. p. 293-315.
  • 51. Elliott T., Tebbs S. Prevention of CVC-related infection. J Hosp Infect 1998; 40:193-201.
  • 52. Chaiyakunapruk N., Veenstra D., Lipsky B., Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002; 136:792-801.
  • 53. Finch R., Greenwood D., Norrby R., Whitley R., editors. Antibiotic and chemotherapy. 8th ed. Philadelphia:Churchill Livingstone; 2003. p. 588-94.
  • 54. Veenstra D., Saint S., Saha S., et al. Efficacy of anticeptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA 1999; 3:261-7.
  • 55. Darouiche R. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis 1999; 29:1371-7.
  • 56. Leon C., Ruiz-Santana S., Rello J., et al. Benefits of minocycline and rifampin-impregnated central venous catheters. Intensive Care Medecine 2004; 30:1891-9.
  • 57. Yucel N., Lefering R., Maegele M., et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. J Antimicrob Chemother 2004; 54:1109-15.
  • 58. Schierholz J., Fleck C., Beuth J., Pulverer G. The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity. J Antimicrob Chemother 2000; 46:45-50.
  • 59. Bong J., Kite P., Wilco M., McMahon M. Prevention of catheter related infection by silver iontophoretic central venous catheters: a randomized controlled trial. J Clin Pathol 2003; 56:731-5.
  • 60. Walder B., Pittet D. Prevention of bloodstream infections with central venous catheters treated with antiinfective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect Control Hosp Epidemiol 2002; 23:748-56.
  • 61. James M.T., Conley J., Tonelli M., et al. Metaanalysis:antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008; 148:596-605.
  • 62. Betjes M.G.H. Prevention of catheter-related bloodstream infection in patients on hemoialysis. Nat Rev Nephrol 2011; 7:257-65.
  • 63. Chow K.M., Poon Y.L., Lam M.P., et al. Antibiotic lock solutions for the prevention of catheter-related bacteraemia in haemodialysis patients. Hong Kong Med J 2010; 16:269-74.
  • 64. Chatzinikolaou I., Zipf T., Hanna H., et al. Minocyclineethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 2003; 36:116-9.
  • 65. Torres-Viera C., Thauvin-Eliopoulos C., Souli M., et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-4.
  • 66. Blenkharn J.I. Antibacterial and related properties of taurolin - a survey. In: Reding R., Verlag T.M., eds. Chirurgische Gastroenterologie mit Interdisziplinaren Gesprachen, NeptunSymposium Rostock. International Communications and Translations (ICA) no. 30871. Philadelphia: ICA, 1991:143-51.
  • 67. Blenkharn J.I. Prevention of septic complications associated with TPN. J Parenter Enter Nutr 1986; 10:436-7.
  • 68. Saint S., Savel R., Matthay M. Enhancing the safety of critically patients by reducing urinary and central venous catheter-related infections. Am J Resp Crit Care Med 2002; 165:1475-9.
  • 69. Buturovic J., Ponikva R., Kandus A., et al. Filling hemodialysis catheters in the interdialic period. Heparin versus citrate versus polygeline: a prospective randomised study. Artif Organs 1998; 22:945-7.
  • 70. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant 2002; 17(S7):72-87.
  • 71. Shineheld H., Black S., Fattom A., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared